Research programme - cancer therapeutics - AIGEN Sciences
Alternative Names: AIG-onco2; AIG-onco3; AIG-onco4Latest Information Update: 15 Feb 2024
At a glance
- Originator AIGEN Sciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 15 Feb 2024 Research programme - cancer therapeutics - AIGEN Sciences is available for licensing as of 15 Feb 2024. https://www.aigensciences.com/rd-pipeline (AIGEN Sciences pipeline, February 2024)
- 02 Feb 2024 Early research in Solid tumours in South Korea (unspecified route) (AIGEN Sciences pipeline, February 2024)
- 02 Feb 2024 AIGEN Sciences plans to file IND application in Solid tumours in 2025 (AIGEN Sciences pipeline, February 2024)